Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]

Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention failed. In a trabeculectomy, number of clinical trials have shown the efficacy of ranibizumab in minimizing extracellular matrix accumulation at the filtering site. Ranibizumab (Lucenti...

Full description

Bibliographic Details
Published in:Sains Malaysiana
Main Author: Noh S.M.M.; Kadir S.H.S.A.; Vasudevan S.
Format: Article
Language:English
Published: Penerbit Universiti Kebangsaan Malaysia 2021
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116266178&doi=10.17576%2fjsm-2021-5009-17&partnerID=40&md5=0f36a0d30a34f7add201b83cd4ec14ad
id 2-s2.0-85116266178
spelling 2-s2.0-85116266178
Noh S.M.M.; Kadir S.H.S.A.; Vasudevan S.
Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]
2021
Sains Malaysiana
50
9
10.17576/jsm-2021-5009-17
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116266178&doi=10.17576%2fjsm-2021-5009-17&partnerID=40&md5=0f36a0d30a34f7add201b83cd4ec14ad
Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention failed. In a trabeculectomy, number of clinical trials have shown the efficacy of ranibizumab in minimizing extracellular matrix accumulation at the filtering site. Ranibizumab (LucentisTM) is a drug that targets vascular endothelial growth factor (VEGF). However, to date the actual mechanisms of this anti-VEGF in trabeculectomy is still not well understood. Hence, in here we aimed to elucidate the effects of ranibizumab on human Tenon's fibroblast (HTF) isolated from patients undergoing trabeculectomy. In our previous study, we had reported that ranibizumab reduces the level of spermidine metabolite whereby spermidine is an important polyamine for cell proliferation. For this current study, cultured HTFs were divided into untreated, control IgG, ranibizumab only, difluoromethylornithine (DFMO; inhibitor of spermidine) only and ranibizumab with DFMO. All cells were extracted for PCR array (expression of CDKN1A, CDK2, and CDK4) and protein expression of p53, p21, CDK2, and CDK4 by Western Blot. In here, our result demonstrated that cells treated with ranibizumab or DFMO and cells treated with ranibizumab-DFMO have similar effects as both show increased in p53 and p21. Meanwhile, no significant differences in expression of CDKN1A, CDK2 and CDK4 were observed in all groups. In essence, our findings suggest that ranibizumab action is mediated by p21 and p53. © 2021 Penerbit Universiti Kebangsaan Malaysia. All rights reserved.
Penerbit Universiti Kebangsaan Malaysia
01266039
English
Article
All Open Access; Gold Open Access
author Noh S.M.M.; Kadir S.H.S.A.; Vasudevan S.
spellingShingle Noh S.M.M.; Kadir S.H.S.A.; Vasudevan S.
Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]
author_facet Noh S.M.M.; Kadir S.H.S.A.; Vasudevan S.
author_sort Noh S.M.M.; Kadir S.H.S.A.; Vasudevan S.
title Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]
title_short Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]
title_full Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]
title_fullStr Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]
title_full_unstemmed Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]
title_sort Ranibizumab inhibits human tenon's fibroblast proliferation via p21 dependent p53 mechanisms; [Ranibizumab merencat percambahan fibroblas tenon manusia melalui mekanisme p21 bersandar p53]
publishDate 2021
container_title Sains Malaysiana
container_volume 50
container_issue 9
doi_str_mv 10.17576/jsm-2021-5009-17
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85116266178&doi=10.17576%2fjsm-2021-5009-17&partnerID=40&md5=0f36a0d30a34f7add201b83cd4ec14ad
description Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention failed. In a trabeculectomy, number of clinical trials have shown the efficacy of ranibizumab in minimizing extracellular matrix accumulation at the filtering site. Ranibizumab (LucentisTM) is a drug that targets vascular endothelial growth factor (VEGF). However, to date the actual mechanisms of this anti-VEGF in trabeculectomy is still not well understood. Hence, in here we aimed to elucidate the effects of ranibizumab on human Tenon's fibroblast (HTF) isolated from patients undergoing trabeculectomy. In our previous study, we had reported that ranibizumab reduces the level of spermidine metabolite whereby spermidine is an important polyamine for cell proliferation. For this current study, cultured HTFs were divided into untreated, control IgG, ranibizumab only, difluoromethylornithine (DFMO; inhibitor of spermidine) only and ranibizumab with DFMO. All cells were extracted for PCR array (expression of CDKN1A, CDK2, and CDK4) and protein expression of p53, p21, CDK2, and CDK4 by Western Blot. In here, our result demonstrated that cells treated with ranibizumab or DFMO and cells treated with ranibizumab-DFMO have similar effects as both show increased in p53 and p21. Meanwhile, no significant differences in expression of CDKN1A, CDK2 and CDK4 were observed in all groups. In essence, our findings suggest that ranibizumab action is mediated by p21 and p53. © 2021 Penerbit Universiti Kebangsaan Malaysia. All rights reserved.
publisher Penerbit Universiti Kebangsaan Malaysia
issn 01266039
language English
format Article
accesstype All Open Access; Gold Open Access
record_format scopus
collection Scopus
_version_ 1814778505167110144